HAPVIDA (HAPV3) Main Indicators
Basic Data - HAPV3
| Company | HAPVIDA |
| Corporate Name | HAPVIDA PARTICIPACOES E INVESTIMENTOS SA |
| Registration Status | ATIVO |
| Issuer Status | FASE OPERACIONAL |
| Listing Segment | Novo Mercado |
| Activity | Participação. como sócia ou acionista. em outras empresas. predominantemente de assistência médica. bem como a realização de investimentos diretos e a exploração de atividades de prestação de serviços |
| Share | HAPV3 |
| Quote Date | 04/01/2025 |
| Share Type | ON |
| Last Closing | R$ 2.22 |
| Quotation Factor | 1 Share |
| Financial Volume | R$ 115.68 M |
| Last Statement | DFP - 12/31/2024 |
| Sector | Saúde |
| Subsector | Serv.Méd.Hospit..Análises e Diagnósticos |
| Segment | Serv.Méd.Hospit..Análises e Diagnósticos |
| Participation Indexes | IBOVESPA, IBRA, IBRX, IBRX50, ICON, IGC, IGCT, IGNM, ITAG, IVBX, MLCX |
| Updated 04/02/2025 | |
Relative Prices - HAPV3
| Price/Earnings | -25.78 |
| Price/SBV | 0.34 |
| Price/Net Sales | 0.58 |
| Price/CFO | 6.14 |
| Price/FCF | 7.56 |
| Price/Total Assets | 0.23 |
| Price/EBIT | 22.59 |
| Price/Working Capital | 2.88 |
| Price/NCAV | -0.88 |
| EV/EBIT | 39.00 |
| EV/EBITDA | 19.34 |
| EV/Net Sales | 1.00 |
| EV/CFO | 10.60 |
| EV/FCF | 13.06 |
| EV/Total Assets | 0.39 |
| Company Market Cap | R$ 16.74 B |
| Enterprise Value | R$ 28.90 B |
| Current Financial Statement Date | 12/31/2024 |
| Current Share Price | R$ 2.22 |
| Share Price Date | 04/01/2025 |
| Dividend Yield | 0.00% |
| Updated 04/02/2025 | |
Income Statement - HAPV3
| Net Revenue | R$ 28.91 B |
| Gross Result | R$ 3.30 B |
| EBIT | R$ 740.99 M |
| Depreciation and Amortization | - R$ 753.11 M |
| EBITDA | R$ 1.49 B |
| Net Profit | - R$ 649.30 M |
| Net Profit/Share | - R$ 0.09 |
| Updated 03/19/2025 | |
| Net Revenue | R$ 7.41 B |
| Gross Result | R$ 1.14 B |
| EBIT | R$ 302.35 M |
| Depreciation and Amortization | R$ 117.45 M |
| EBITDA | R$ 184.90 M |
| Net Profit | - R$ 251.96 M |
| Profit/Share | - R$ 0.03 |
| Updated 03/19/2025 | |
Price and Volume Behavior - HAPV3
| Lowest Price 52 weeks | R$ 2.05 |
| Highest Price 52 weeks | R$ 4.66 |
| Variation 2025 | 2.30% |
| Variation 1 year | -43.65% |
| Variation 2 years(total) | -15.27% |
| Variation 2 years(yearly) | -7.93% |
| Variation 3 years(total) | -82.02% |
| Variation 3 years(yearly) | -43.53% |
| Variation 4 years(total) | -84.99% |
| Variation 4 years(yearly) | -37.74% |
| Variation 5 years(total) | -72.11% |
| Variation 5 years(yearly) | -22.53% |
| Average Daily Volume (3 months) | R$ 220.29 M |
| Updated 04/02/2025 | |
Returns and Margins - HAPV3
| Return on Initial Tangible Capital | 2.89% |
| Return on Initial Invested Capital | 0.82% |
| Pre-Tax Return on Initial Tangible Capital | 4.38% |
| Pre-Tax Return on Initial Invested Capital | 1.25% |
| Return on Initial Shareholder´s Equity | -1.32% |
| Return on Initial Asset | -0.89% |
| Gross Margin | 11.42% |
| Net Margin | -2.25% |
| EBIT Margin | 2.56% |
| EBITDA Margin | 5.17% |
| Initial Asset Turnover | 0.40 |
| Financial Leverage | 1.51 |
| Liabilities/Net Worth | 0.51 |
| Net Debt/EBITDA | 8.14 |
| Updated 03/19/2025 | |
Balance Sheet - HAPV3
| Cash and Cash Equivalents | R$ 596.75 M |
| Total Assets | R$ 73.50 B |
| Short-Term Debt | R$ 950.84 M |
| Long-Term Debt | R$ 11.80 B |
| Gross Debt | R$ 12.75 B |
| Net Debt | R$ 12.16 B |
| Shareholder´s Equity | R$ 48.68 B |
| Share Book Value | R$ 6.46 |
| Common Shares | 7,539,463,263 |
| Preferred Shares | 0 |
| Total | 7,539,463,263 |
| Common Shares in Treasury | 119,673,213 |
| Preferred Shares in Treasury | 0 |
| Total in Treasury | 119,673,213 |
| Common Shares (Except Treasury) | 7,419,790,050 |
| Preferred Shares (Except Treasury) | 0 |
| Total (Except Treasury) | 7,419,790,050 |
| Updated 03/19/2025 | |
Cash Flow - HAPV3
| Operating Cash Flow | R$ 2.73 B |
| Cash Flow from Investments | - R$ 2.23 B |
| Financing Cash Flow | - R$ 1.32 B |
| Increase (Reduction) in Cash and Equivalents | - R$ 818.51 M |
| Updated 03/19/2025 | |
| Operating Cash Flow | R$ 561.95 M |
| Cash Flow from Investments | - R$ 1.36 B |
| Financing Cash Flow | R$ 907.65 M |
| Increase (Reduction) in Cash and Equivalents | R$ 107.91 M |
| Updated 03/19/2025 | |
Experimental - HAPV3
| CAPEX 3 months | - R$ 334.15 M |
| Free Cash Flow 3 months | R$ 227.81 M |
| CAPEX 12 months | - R$ 513.48 M |
| Free Cash Flow 12 months | R$ 2.21 B |
| Updated 03/19/2025 | |